Finance

Lists
IMTX:NASDAQ
Immatics NV
$6.39
-1.99%
(-0.13) 1D
$6.39
0.00% (0.00)
After hours
Closed: Nov 13, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for IMTX...
Open
$6.49
High
$6.54
Low
$6.08
Mkt. cap
972.98M
Avg. vol.
1.10M
Volume
586.39K
52-wk high
$12.40
52-wk low
$6.08
EPS
-$1.76
Beta
1.38
Shares outstanding
149.64M
No. of employees
704
Open
$6.49
High
$6.54
Low
$6.08
Mkt. cap
972.98M
Avg. vol.
1.10M
Volume
586.39K
52-wk high
$12.40
52-wk low
$6.08
EPS
-$1.76
Beta
1.38
Shares outstanding
149.64M
No. of employees
704
News stories
From web sources and news partners
About Immatics NV
CEOHarpreet Singh
Employees704
Founded2000
Headquarters-
SectorHealth Care
IndustryBiotechnology
Analyst ratings
Based on 6 analysts giving stock ratings to IMTX in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for IMTX in the last 3 months.
Highest
Current $6.39
$21.00 (+228.64%)
Average
$15.76 (+146.64%)
Lowest
$11.80 (+84.66%)
Analyst
Recommendation
Action
Price target
Projected
Date
Alec Stranahan
Bank of America Securities
Buy
Reiterated
$14.00
+119.1%
11/13/2026
Graig Suvannavejh
Mizuho Securities
Buy
Maintained
$21.00
+228.6%
10/29/2026
Laura Prendergast
Stifel Nicolaus
Buy
Maintained
$15.00
+134.7%
10/26/2026
Faisal Khurshid
Jefferies
Buy
Reiterated
$17.00
+166%
08/25/2026
Nicholas Lorusso
TD Cowen
Buy
Maintained
-
-
08/18/2026
Rajan Sharma
Goldman Sachs
Buy
Maintained
$11.80
+84.7%
08/18/2026
Geulah Livshits
Chardan Capital
Buy
Reiterated
$25.00
+291.2%
05/19/2026
Paul Jeng
Guggenheim
Buy
Maintained
$19.00
+197.3%
05/12/2026
Unknown Analyst
Goldman Sachs
Buy
Maintained
$12.20
+90.9%
05/13/2026
Jonathan Chang
Leerink Partners
Buy
Reiterated
$17.00
+166%
03/06/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in EUR
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
19.76M
7.61M
9.14M
6.92M
Cost of goods sold
49.64M
59.19M
62.41M
-
Cost of revenue
49.64M
59.19M
62.41M
-
Research and development expenses
-
-
-
70.27M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
13.66M
14.51M
13.94M
15.81M
Operating expense
9.00M
14.49M
13.94M
85.46M
Total operating expenses
58.64M
73.68M
76.35M
85.46M
Operating income
-38.88M
-66.06M
-67.20M
-78.54M
Other non operating income
15.00K
-30.00K
54.00K
2.55M
EBT including unusual items
-35.56M
-57.76M
-62.77M
-76.43M
EBT excluding unusual items
-35.56M
-57.76M
-62.77M
-76.43M
Income tax expense
134.00K
52.00K
-274.00K
-407.00K
Effective tax rate
-0.38%
-0.09%
0.44%
0.53%
Other operating expenses
-4.66M
-24.00K
-
-615.00K
Net income
-35.70M
-57.81M
-62.49M
-76.02M
Net profit margin
-180.65%
-759.51%
-683.42%
-1,098.11%
Earnings per share
-
-
-
-
Interest and investment income
3.55M
3.58M
3.29M
-
Interest expense
-222.00K
-212.00K
-203.00K
-440.00K
Net interest expenses
3.33M
3.37M
3.08M
-440.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-36.60M
-63.29M
-64.20M
-75.66M
Gain or loss from assets sale
593.00K
48.00K
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps